Kaisa V.
- Country
- Finland
- Department
- Department of paediatrics
Research Overview
- International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
- Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
- Evaluation of Quizartinib in Combination with Chemotherapy for Pediatric FLT3-ITD Positive, NPM1 Wild-Type Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 212 of 331 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating various forms of pediatric blood cancers, with particular focus on acute myeloid leukemia and acute lymphoblastic leukemia in children and young adults.
- Advanced lymphoma treatments
- B-cell malignancies
- Pediatric leukemia management
Active involvement in innovative therapeutic approaches for anaplastic large cell lymphoma and B-cell lymphomas.
Pediatric Solid Tumors
Dedicated to advancing treatment options for rhabdomyosarcoma and other pediatric soft tissue malignancies. Expertise in managing ependymoma and complex brain tumors in young patients.
- Sarcoma therapeutics
- Neuro-oncology
- Multimodal treatment approaches
Focuses on integrating surgical, radiotherapy, and systemic treatment strategies for optimal patient outcomes.
Therapeutic Innovation
Leads development of targeted therapies including immunotherapy applications and novel drug combinations for pediatric cancers.
- Precision medicine approaches
- Risk-adapted therapy protocols
- Treatment intensification strategies
Specializes in developing personalized treatment protocols based on molecular and clinical risk factors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.